Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis (NCT03097315) | Clinical Trial Compass
CompletedPhase 3
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
United States38 participantsStarted 2017-04-04
Plain-language summary
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of active or inactive non-infectious uveitis (pan, anterior, intermediate and posterior)
* ETDRS BCVA score of ≥ 5 letters read in the study eye
Exclusion Criteria:
* Any active ocular disease or infection in the study eye other than uveitis
* Intraocular pressure \> 22 mmHg or uncontrolled glaucoma in the study eye; patients with IOP of 22 or less in the study eye not excluded with no more than 2 IOP-lowering medications.
* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study
* Any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an OZURDEX implant in the 6 months prior to baseline; RETISERT or ILUVIEN implant in the 3 years prior to baseline.